Post-translational Modification of Delta Antigen of Hepatitis D Virus

Author(s):  
W. -H. Huang ◽  
C. -W. Chen ◽  
H. -L. Wu ◽  
P. -J. Chen
2002 ◽  
Vol 277 (36) ◽  
pp. 33058-33067 ◽  
Author(s):  
Chi-Wu Chen ◽  
Yeou-Guang Tsay ◽  
Hui-Lin Wu ◽  
Chi-Hua Lee ◽  
Ding-Shinn Chen ◽  
...  

2004 ◽  
Vol 85 (4) ◽  
pp. 947-957 ◽  
Author(s):  
Ko-Nien Shih ◽  
Ya-Ting Chuang ◽  
Hsuan Liu ◽  
Szecheng J. Lo

During its life cycle, hepatitis D virus (HDV) produces two forms of delta antigen (HDAg), small delta antigen (SDAg) and large delta antigen (LDAg), which differ in their C-terminal 19 amino acids. Host enzymes termed ADARs (adenosine deaminases that act on double-stranded RNA) are required for LDAg production. These enzymes change the stop codon (UAG) of SDAg to a tryptophan codon (UGG). However, the temporal and spatial regulation of HDV RNA editing is largely unknown. In this study, we constructed three GFP fusion proteins containing different lengths of SDAg and characterized their cellular localization and effects on HDV replication. One of these fusion proteins, designated D(1–88)-GFP, inhibited LDAg but not SDAg production, suggesting that D(1–88)-GFP inhibits HDV RNA editing. Two experiments further supported this supposition: (i) RT-PCR analysis combined with NcoI restriction enzyme digestion revealed that HDV RNA editing was reduced by 42 % in HeLa-D(1–88)-GFP when compared with HeLa cells; and (ii) the ratio of SDAg/LDAg production from the reporter RNAs was reduced in cells co-transfected with ADAR-expressing and reporter plasmids in the presence of D(1–88)-GFP. Double fluorescence microscopy found that D(1–88)-GFP was either associated with SC-35 or was adjacent to PML (premyelocytic leukaemia antigen) at nuclear speckles, but D(1–88)-GFP was not co-localized with ADAR, which was mainly located in the nucleolus. In situ hybridization showing co-localization of HDV RNA with D(1–88)-GFP at nuclear speckles suggested that HDV RNA editing might occur in the nuclear speckles and require other nuclear factor(s), in addition to ADAR.


1992 ◽  
Vol 39 (4) ◽  
pp. 231-234 ◽  
Author(s):  
MASAYOSHI KAGE ◽  
KENICHIRO KOSAI ◽  
KAZUHIDE SHIMAMATSU ◽  
OSAMU NAKASHIMA ◽  
MAKOTO HARAMAKI ◽  
...  

Gut ◽  
2021 ◽  
pp. gutjnl-2020-323888
Author(s):  
Stephan Urban ◽  
Christoph Neumann-Haefelin ◽  
Pietro Lampertico

Approximately 5% of individuals infected with hepatitis B virus (HBV) are coinfected with hepatitis D virus (HDV). Chronic HBV/HDV coinfection is associated with an unfavourable outcome, with many patients developing liver cirrhosis, liver failure and eventually hepatocellular carcinoma within 5–10 years. The identification of the HBV/HDV receptor and the development of novel in vitro and animal infection models allowed a more detailed study of the HDV life cycle in recent years, facilitating the development of specific antiviral drugs. The characterisation of HDV-specific CD4+ and CD8+T cell epitopes in untreated and treated patients also permitted a more precise understanding of HDV immunobiology and possibly paves the way for immunotherapeutic strategies to support upcoming specific therapies targeting viral or host factors. Pegylated interferon-α has been used for treating HDV patients for the last 30 years with only limited sustained responses. Here we describe novel treatment options with regard to their mode of action and their clinical effectiveness. Of those, the entry-inhibitor bulevirtide (formerly known as myrcludex B) received conditional marketing authorisation in the European Union (EU) in 2020 (Hepcludex). One additional drug, the prenylation inhibitor lonafarnib, is currently under investigation in phase III clinical trials. Other treatment strategies aim at targeting hepatitis B surface antigen, including the nucleic acid polymer REP2139Ca. These recent advances in HDV virology, immunology and treatment are important steps to make HDV a less difficult-to-treat virus and will be discussed.


Sign in / Sign up

Export Citation Format

Share Document